

REMARKS

This amendment responds to the office action mailed April 6, 2005. Prior to entry of this amendment, claims 38-71 and 73-94 were pending and under consideration in the instant Application. With this amendment, claims 38-71 and 73-94 are cancelled, and new claims 95-130 are presented for consideration. Thus, following entry of this amendment, claims 95-130 are pending and under consideration.

Applicants kindly thank Examiner Winkler for her remarkable courtesy during the interview on December 19, 2005.

I. The Amendments to the Claims

This paper presents an amendment canceling claims 38-71 and 73-94 and adding new claims 95-130. The new claims 95-130 are fully supported by the application as filed, and thus do not present new matter. In particular, support for new claims 95-130 may be found, for example, in claims 1-34 as filed.

Since new claims 95-130 are fully supported by the application as filed and do not present new matter, and Applicants have filed herewith a Request for Continued Examination, Applicants respectfully request entry of the amendment to the claims under 37 C.F.R. § 1.116.

II. Interview Summary

Applicants kindly thank Examiner Winkler for granting an Interview with Applicants' representative, H. Thomas Anderton, and Applicants Christos Petropoulos and Neil Parkin, on December 19, 2005. Examiner Winkler's summary (mailed December 21, 2005) accurately reflects the substance of the interview.

III. The Rejections of Claims 38-71, 73-76, and 78-94 under 35 U.S.C. § 112, Second Paragraph

Claims 38-71, 73-76, and 78-94 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly indefinite. Applicants have cancelled claims 38-71, 73-76, and 78-94. Accordingly, the rejection of claims 38-71, 73-76, and 78-94 is moot, and Applicants respectfully request that the rejection under 35 U.S.C. § 112, second paragraph, be withdrawn with respect to the new claims.

IV. The Obviousness Rejection under 35 U.S.C. § 103(a)

Claims 38-71, 73-76, and 78-94 stand rejected under 35 U.S.C. § 103(a) as allegedly obvious over Gao *et al.*, 1996, *Journal of Virology*, 70:1651-1667 ("Gao") and Petropoulos *et al.*, 2000, *Antimicrob. Agents. Chemother.*, 44:920-928 ("Petropoulos") in view of Grovit-Ferbas *et al.*, 1998, *Journal of Virology*, 72:8650-8658 ("Grovit") and Trkola *et al.*, 1999, *Journal of Virology*, 73:8966-8974 ("Trkola").

As agreed during the interview, the Declaration of Dr. Robert C. Doms, coupled with the new claims submitted herewith, overcomes any of the above-stated rejections. Accordingly, Applicants respectfully request that the rejection under 35 U.S.C. § 103(a) be withdrawn.

CONCLUSION

In light of the above amendments and remarks, Applicants respectfully submit that claims 95-130 satisfy all the criteria for patentability and are in condition for allowance. Applicants respectfully request that the Examiner reconsider this application with a view towards allowance and solicit an early passage of claims 95-130 to issuance. Further, Applicants respectfully request that the Examiner telephone H. Thomas Anderton at (650) 624-4198 prior to issuance of another Office Action should the Examiner be inclined to issue another Office Action rather than a Notice of Allowance.

Pursuant to 37 CFR § 1.136(a)(3), the Commissioner is hereby authorized to charge all required fees, including fees under 37 CFR § 1.17 and all required extension of time fees, or credit any overpayment, to Jones Day Deposit Account No. 503013 (order no. 101920-999050).

Respectfully submitted,

Date: March 6, 2006



David C. Pauling 56,056
(Reg. No.)

For: Nikolaos C. George (Reg. No. 39,201)
JONES DAY
222 East 41st Street
New York, NY 10017
(212) 326-3939